Another study showed that polymorphisms in transcription factor binding sites (TFBs), such as the TPH2 rs34517220 polymorphism, were significantly associated with improved symptoms of depression in children (mean age: 14.7 years) following Fluoxetine treatment [79]. The gene discussed is TPH2; the disease is major depressive disorder.